- In June 2024, Gilead Sciences presented the new research at the 2024 European Association for the Study of the Liver (EASL) Congress in Milan, focusing on liver diseases such as primary biliary cholangitis (PBC), hepatitis B (HBV), hepatitis delta virus (HDV), and others. Key presentations will include long-term data from the ASSURE study on seladelpar for PBC, results on tenofovir for liver cancer prevention in HBV, and findings from the MYR204 and MYR301 studies on Hepcludex for HDV. This research highlights Gilead's commitment to advancing treatment options for liver diseases
- In October 2024, Intercept Pharmaceuticals, Inc discussed their ongoing efforts to explore racial differences and disparities in Primary Biliary Cholangitis (PBC) care. The company is addressing how various populations may face different challenges in the diagnosis, treatment, and management of PBC. By exploring these disparities, Intercept aims to improve access to care and treatment outcomes for all patients, potentially reducing barriers to effective treatment of liver diseases, including fibrosis
- In November 2022, The U.S. Food and Drug Administration (FDA) approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. This approval extends the use of Vemlidy, which was initially approved in 2016 for adults with chronic HBV. The approval is based on a Phase 2 clinical trial demonstrating Vemlidy’s efficacy and safety in this younger patient group
- In September 2022, Gilead Sciences completed its acquisition of MiroBio, a UK-based biotechnology company focused on restoring immune balance through agonists targeting immune inhibitory receptors. The acquisition, valued at approximately $405 million, provides Gilead with MiroBio’s discovery platform and its portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, targets immune cells to suppress inflammatory immune responses and is currently in Phase 1 clinical trials. This acquisition enhances Gilead's efforts in addressing chronic immune-mediated conditions
- In March 2021, Gilead Sciences and Novo Nordisk expanded their collaboration in the treatment of non-alcoholic steatohepatitis (NASH) by initiating a Phase 2b clinical trial. The study investigates the safety and efficacy of semaglutide, a GLP-1 receptor agonist from Novo Nordisk, combined with Gilead's cilofexor (an FXR agonist) and firsocostat (an ACC inhibitor) in patients with cirrhosis due to NASH. The trial will assess the treatments' impact on liver fibrosis and NASH resolution, with recruitment expected to start in the second half of 2021
